KYMR Q3 2023 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-50.5% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$58M-1216.3% margin

Net Income

-$53M-1118.2% margin

EPS (Diluted)

$-0.90

QoQ Revenue Growth

-71.4%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$40M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$552M

Total Liabilities

$157M

Stockholders' Equity

$396M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$10M	-50.5%
Gross Profit	$5M	$10M	-50.5%
Operating Income	-$58M	-$45M	-28.1%
Net Income	-$53M	-$43M	-22.9%